Top Section/Ad
Top Section/Ad
Most recent
The winning institutions, deals and individuals revealed at our inaugural gala dinner in London
Last chance to submit nominations for yourself, your clients and peers in the GlobalCapital's US Securitization Awards
GlobalCapital invites market participants to nominate their clients, their peers, and themselves in its 2026 US Securitization Awards
GlobalCapital is pleased to announce the shortlists and open the main voting round for the European Securitization Awards 2026
More articles/Ad
More articles/Ad
More articles
-
The Lion Power consortium succeeded in its acquisition of Senoko Power of Singapore by arranging a very aggressive level of debt funding in what were tumultuous credit markets after the collapse of Lehman Brothers. It was the largest acquisition debt facility for a utility deal in Asia last year and earns Asiamoney's award.
-
The Series 1 Filp Master Trust 1st SPC asset-backed securities issue collateralised a pool of public sector loans. Conducted in February, it was the first transaction in what promises to be a vibrant new form of securitisation in Japan.
-
US corporate Wal-Mart became the first retailer to tap the Samurai bond market in almost 30 years last July. With its AA credit rating it provided much-needed high-grade corporate diversification in a difficult environment. Local investor interest was strong, pricing was tight and coupons on the tranches were appealing.
-
Seven Bank’s debut listing was the nation's largest IPO last year. Because of the bank’s unique business model, its shares have outperformed the Japanese stock market since, impressive at a time when most bank shares have sunk amid the climate of investor fear.
-
Yamada Denki became the first firm in Japan to use a convertible bond to conduct a recapitalisation and share buy-back. The February offering, which has since been emulated, helped to lower company costs while creating value for existing shareholders in turbulent times.
-
Takeda Pharma’s acquisition of drugs-maker Millennium last May cemented it as a global force in pharmaceuticals. The deal offered a number of synergies and represented the pinnacle of a Japanese market trend.